Nivolumab for advanced skin squamous cell cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial studies nivolumab, an immune therapy, for skin squamous cell cancer that can’t be cured with surgery or radiation. It aims to see how well the treatment shrinks tumors and helps people live longer or longer without cancer growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re 18 or older and can sign consent for the study
- You have skin squamous cell cancer that is locally advanced or has spread, and it’s not curable
- You have tumor tissue available from past tests so they can study immune markers (PD-L1 and LAG-3)
- Your cancer has measurable targets on scans or exams, and you’re expected to live at least 12 weeks
- Your blood work, kidney function, and liver tests are strong enough for treatment (within set limits)
- You haven’t had certain recent cancer study treatments or previous immune drugs that block PD-1, CTLA-4, or LAG-3
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if two immunotherapy drugs, nivolumab and relatlimab, given before surgery can help shrink a type of skin cancer called cutaneous squamous cell carcinoma. It's for people whose cancer can be removed with surgery.
This study tests how well the immunotherapy medicine nivolumab works—either by itself or combined with other immune-boosting drugs—for people with advanced basal cell carcinoma that can’t be removed by surgery or has spread. It’s also looking at what to do if the cancer grows again after an earlier immunotherapy.
This trial tests a lower dose of nivolumab (an immunotherapy drug) given less frequently to treat cancers that have spread or cannot be surgically removed. The goal is to see if this approach works well while reducing side effects compared to standard dosing.
This trial tests a combination of three drugs—two chemotherapy medications (carboplatin and nab-paclitaxel) plus an immunotherapy drug (serplulimab)—as a first-line treatment for advanced squamous cell non-small cell lung cancer. The goal is to see if this combination works better than standard treatment and is safe for patients who haven't received prior systemic cancer treatment.
This trial tests a very short course of immunotherapy (nivolumab) before standard surgery for patients with certain types of advanced or hard-to-treat skin cancer (cutaneous squamous cell carcinoma). The goal is to see if this approach can reduce the need for extensive or disfiguring surgery.
This trial tests if giving a combination of two immunotherapy drugs (nivolumab and relatlimab) before surgery works better than one drug alone for people with large or high-risk basal cell skin cancer that needs surgery. The goal is to shrink the cancer and make surgery easier.
Hear when a new Squamous Cell Carcinoma of the Skin trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.